Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former Smokers
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2019
Price : $35 *
At a glance
- Drugs Curcumin (Primary) ; Omega-3-acid ethyl esters (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 16 Jan 2019 Status changed from not yet recruiting to recruiting.
- 02 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 1 Jun 2019.
- 26 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.